|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010显示文摘Several advances in genetics, diagnosis and palliation of pancreatic cancer (PC) have occurred in the last decades. A multidisciplinary approach to this disease is therefore recommended. PC is relatively common as it is the fourth leading cause of cancer related mortality. Most patients present with obstructive jaundice, epigastric or back pain, weight loss and anorexia. Despite improvements in diagnostic modalities, the majority of cases are still detected in advanced stages. The only curative treatment for PC remains surgical resection. No more than 20% of patients are candidates for surgery at the time of diagnosis and survival remains quite poor as adjuvant therapies are not very effective. A small percentage of patients with borderline non-resectable PC might benefit from neo-adjuvant chemoradiation therapy enabling them to undergo resection; however, randomized controlled studies are needed to prove the benefits of this strategy. Patients with unresectable PC benefit from palliative interventions such as biliary decompression and celiac plexus block. Further clinical trials to evaluate new chemo and radiation protocols as well as identification of genetic markers for PC are needed to improve the overall survival of patients affected by PC, as the current overall 5-year survival rate of patients affected by PC is still less than 5%. The aim of this article is to review the most recent high quality literature on this topic. | Chakshu Sharma Karim M Eltawil Paul D Renfrew Mark J Walsh Michele Molinari | 2011 | World Journal of Gastroenterology2011，17，7： | 28 |
| 2 | Rifaximin vs conventional oral therapy for hepatic encephalopathy:A meta-analysis显示文摘AIM: To characterize the efficacy of rifaximin in the management of hepatic encephalopathy (HE) as several randomized controlled studies have shown contradictory results on its effectiveness in comparison to other oral agents. METHODS: We performed a systematic review and random effects meta-analysis of all eligible trials identifi ed through electronic and manual searches. Twelve randomized controlled trials met the inclusion criteria with a total of 565 patients. RESULTS: The clinical effectiveness of rifaximin was equivalent to disaccharides or other oral antibiotics[odds ratio (OR) 0.96; 95% CI: 0.94-4.08] but with a better safety profi le (OR 0.27; 95% CI: 0.12-0.59). At the completion of treatment protocols, patients receiving rifaximin showed lower serum ammonia levels [weighted mean difference (WMD) = -10.65; 95% CI: -23.4-2.1; P = 0.10], better mental status (WMD = -0.24; 95% CI: -0.57-0.08; P = 0.15) and less asterixis (WMD -0.1; 95% CI -0.26-0.07; P = 0.25) without reaching statistical signifi cance. On the other hand, other psychometric outcomes such as electroencephalographic response and grades of portosystemic encephalopathy were superior in patients treated with rifaximin in comparison to the control group (WMD = 0.21, 95% CI: -0.33-0.09, P = 0.0004; and WMD = -2.33, 95% CI: -2.68-1.98, P = 0.00001, respectively). Subgroup and sensitivity analysis did not show any signifi cant difference in the above fi ndings. CONCLUSION: Rifaximin appears to be at least as effective as other conventional oral agents for the treatment of HE with a better safety profi le. | Karim M Eltawil Marie Laryea Kevork Peltekian Michele Molinari | 2012 | World Journal of Gastroenterology2012，18，8： | 9 |
| 3 | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer显示文摘 | Di Nicolantonio F Martini M Molinari F | 2008 | J Clin Oneol2008，26，35： | 1 |
| 4 | Ca2+-activated neutral protease is active in the erythrocyte membrane in its non-autolyzed 80 kDa form显示文摘 | Molinari M Carafoli E | 1994 | J Biol Chem1994，269，27： | 1 |
| 5 | Wild-type BRAF is required for responseto panitumurnab or cetuximab in metastatic colorectal cancer显示文摘 | DI NICOLANTONIO F MARTINI M MOLINARI F | 2008 | J Clin Oncol2008，26，35： | 1 |
| 6 | Calpain:a protease in search of a function Biochem Biophy Res显示文摘 | Carafoli E Molinari M | 2000 | Commoun2000，247，： | 1 |
| 7 | Reeunstruetion by Panereaticojejunoslomy versus pancreaticogastrostomy following panetateetomy: results of a comparative study显示文摘 | Basi C Faleoni M Molinari | 2005 | Ann surg2005，242，6： | 1 |
| 8 | Prevalence of Theileriaequi and Babesia caballi Infection in Horses from Northern It-aly显示文摘 | Grandi G Molinari G Tittarelli M | 2011 | Vector Borne Zoonotic Dis?2011，23，1： | 1 |
| 9 | PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR- targeted monoclonal antibodies显示文摘 | SARTORE-BIANCHI A MARTINI M MOLINARI F | 2009 | Cancer Res2009，69，5： | 1 |
| 10 | Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial 显示文摘 | Bassi C Falconi M Molinari E | 2003 | Surgery2003，134，5： | 1 |
| 11 | Cell cycle checkpoints and their inactivation in human cancer 显示文摘 | MOLINARI M | 2000 | Cell Prolif2000，33，5： | 1 |
| 12 | Three-dimensional adaptive meshing by subdivision and edge-collapse in finite deformation dynamic-plasticity problems with application to adiabatic shear banding显示文摘 | Molinari JF Ortiz M | 2002 | International Journal for Numerical Methods in Engineering2002，53，5： | 1 |
| 13 | Experimental verification of a diffusion tool wear model using a 42CrMo4 steel with an uncoated cemented tungsten carbide at various cutting speeds 显示文摘 | Nouari M Molinari A | 2005 | Wear2005，259，712： | 1 |
| 14 | Modeling of Tool Wear by Diffusion in Metal Cutting 显示文摘 | Molinari A Nouari M | 2002 | Wear2002，252，12： | 1 |
| 15 | Treatment of aqueous effluents of the leather industry by membrane processes显示文摘 | A Cassano R Molinari M Romano E Drioli | 2001 | Journal of Membrane Science2001，，1： | 1 |
| 16 | Transarterial chemoembo-]isation for advanced hepatocellular carcinoma : results from a NorthAmerican cancer centre 显示文摘 | Molinari M Kachura JR Dixon E | 2006 | Clin Oncol ( R Coll Radiol)2006，189，： | 1 |
| 17 | Constitutive rela- tionships for 22MnB5 boron steel deformed isothermally at high temperatures 显示文摘 | Naderi M Durrenberger L Molinari A | 2008 | Materials Science and Engineering: A2008，478，1： | 1 |
| 18 | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer显示文摘 | Di Nicolantonio F Martini M Molinari F | 2008 | J Clin Oncol2008，26，35： | 1 |
| 19 | Modeling of tool wear by diffusion in metal cutting显示文摘 | Molinari A Nouari M | 2002 | Wear2002，252，1： | 1 |
| 20 | Rostafuroxin protectsfrom podocyte injury and proteinuria induced by adducin geneticvariants and ouabain 显示文摘 | Ferrandi M Molinari I Rastaldi MP | 2014 | J Pharmacol Exp Ther2014，351，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员